List of Excipients in Branded Drug EZETIMIBE

Generic Drugs Containing EZETIMIBE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	ezetimibe	0591-3713	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	ezetimibe	0591-3713	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	ezetimibe	0591-3713	CROSPOVIDONE
Actavis Pharma Inc	ezetimibe	0591-3713	HYPROMELLOSE 2910
Actavis Pharma Inc	ezetimibe	0591-3713	LACTOSE MONOHYDRATE
Actavis Pharma Inc	ezetimibe	0591-3713	MAGNESIUM STEARATE
Actavis Pharma Inc	ezetimibe	0591-3713	SODIUM LAURYL SULFATE

What are the Most Frequently-Used Excipients in EZETIMIBE?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
36	CELLULOSE, MICROCRYSTALLINE
45	CROSCARMELLOSE SODIUM
26	CROSPOVIDONE
1	HYDROXYPROPYL METHYLCELLULOSE
8	HYPROMELLOSE
10	HYPROMELLOSE 2208

Ezetimibe Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: August 25, 2026

Ezetimibe is a mature, orally administered cholesterol-absorption inhibitor with broad generic availability and limited remaining small-molecule exclusivity. Commercial opportunity has shifted from basic immediate-release tablets to differentiated formulations, fixed-dose combinations, pediatric delivery, adherence products, and excipient systems that improve manufacturability, dissolution, stability, or patient acceptability.

The strongest near-term opportunities are low-cost formulation platforms, ezetimibe combinations with statins or bempedoic acid, orally disintegrating or sprinkle products, and formulations designed for patients with swallowing difficulties. Patent protection is more likely to arise from formulation, manufacturing, combination, or use claims than from the original ezetimibe molecule.

What is ezetimibe and how is it used?

Ezetimibe is a selective inhibitor of intestinal cholesterol absorption. It blocks the Niemann-Pick C1-like 1, or NPC1L1, transporter at the intestinal brush border. The FDA approved Zetia, the original ezetimibe product, in 2002 for primary hypercholesterolemia and sitosterolemia. The drug is also used with statins and in fixed-dose combinations.

Ezetimibe product profile

Attribute	Ezetimibe
Active ingredient	Ezetimibe
Mechanism	NPC1L1 cholesterol-absorption inhibition
Common dose	10 mg once daily
Dosage form	Immediate-release oral tablet
Food effect	Can be administered with or without food
Biopharmaceutics	Low aqueous solubility; absorption is formulation-sensitive
Original brand	Zetia
Major combinations	Vytorin with simvastatin; Nexlizet with bempedoic acid
FDA approval	2002 for Zetia
Generic availability	Broadly available in the U.S.
Biosimilar exposure	None; ezetimibe is a synthetic small molecule

Ezetimibe undergoes extensive glucuronidation to ezetimibe-glucuronide, an active metabolite. The parent drug and metabolite undergo enterohepatic recirculation. The molecule is practically insoluble in water, creating formulation opportunities around wetting, particle engineering, dissolution, and dose uniformity.

What excipients are used in ezetimibe tablets?

The original Zetia tablet uses a conventional direct-compression or granulation-compatible excipient system. The FDA labeling identifies lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate in the tablet core. The film coating contains conventional coating materials, including hypromellose and colorants, depending on product presentation. [1]

Core excipient functions

Excipient class	Typical material	Function in ezetimibe tablets
Diluent	Lactose monohydrate	Adds bulk and supports compactability
Diluent and compression aid	Microcrystalline cellulose	Improves tablet strength and disintegration
Binder	Povidone	Supports granule or tablet cohesion
Superdisintegrant	Croscarmellose sodium	Accelerates tablet breakup
Surfactant or wetting agent	Sodium lauryl sulfate	Improves wetting of poorly soluble ezetimibe
Lubricant	Magnesium stearate	Reduces ejection force and tooling adhesion
Film former	Hypromellose	Protects and improves tablet appearance
Opacifier or colorant	Titanium dioxide or iron oxides	Product identification and light protection

The key formulation challenge is balancing wetting and dissolution against processing risks. Sodium lauryl sulfate can improve dispersion of ezetimibe but may affect tabletability, disintegration, taste, and stability. Magnesium stearate can impair wetting if over-lubrication occurs. Croscarmellose sodium must be optimized against compression force and lubricant concentration.

How does ezetimibe solubility affect excipient selection?

Ezetimibe is a low-solubility compound. The formulation therefore needs rapid wetting and efficient breakup without creating excessive manufacturing complexity.

High-value excipient strategies

Surfactant-assisted wetting

Sodium lauryl sulfate is the most direct strategy in the reference formulation. Other surfactants, such as poloxamers, polysorbates, or sodium stearyl fumarate-compatible systems, may be evaluated where the target product requires lower irritation potential or improved processing.

The commercial value is highest when a sponsor can demonstrate:

• Faster dissolution at clinically relevant pH values.
• Lower dissolution variability across tablet strengths.
• Reduced sensitivity to particle-size variation.
• Improved stability under humidity stress.
• Compatibility with continuous manufacturing.

Particle-size reduction

Micronized ezetimibe can reduce the diffusion distance and increase surface area. Particle engineering may be combined with a wetting agent or hydrophilic carrier. The limitation is that smaller particles can agglomerate, reduce flow, and create blend-uniformity problems at the 10 mg dose.

A patentable position may require more than a generic particle-size limitation. Stronger claims typically connect particle size or distribution to a defined dissolution profile, bioavailability result, manufacturing process, or stability outcome.

Amorphous and solid-dispersion systems

Amorphous ezetimibe or an ezetimibe solid dispersion may improve apparent solubility. Suitable carriers can include povidone, copovidone, hydroxypropyl methylcellulose acetate succinate, polyethylene glycol, or related polymer systems.

The main technical risks are recrystallization, moisture uptake, residual solvent, and scale-up. A solid-dispersion product has stronger differentiation potential than a standard tablet but carries higher development and regulatory burden.

Lipid-based systems

Self-emulsifying or lipid-based formulations may increase apparent solubilization. These systems are more commercially relevant for softgels, liquid-filled capsules, or specialized oral products than for a low-cost generic tablet.

The main barriers are capsule compatibility, content uniformity, oxidation, excipient qualification, food-effect characterization, and manufacturing cost.

What formulations are protected or commercially differentiated for ezetimibe?

The original commercial product is an immediate-release 10 mg tablet. The largest commercial differentiation has come from combination products rather than from a novel standalone ezetimibe dosage form.

Formulation and delivery opportunities

Product concept	Technical rationale	Commercial attractiveness
Standard immediate-release tablet	Low-cost, established regulatory pathway	Low to moderate
Smaller tablet	Improves swallowing and adherence	Moderate
Orally disintegrating tablet	Supports dysphagia and adherence markets	Moderate to high
Chewable tablet	Pediatric or geriatric positioning	Moderate
Sprinkle granules	Useful for patients unable to swallow tablets	Moderate
Amorphous solid dispersion	Addresses dissolution and dose consistency	Moderate to high
Liquid suspension	Pediatric and enteral-tube use	Moderate
Fixed-dose statin combination	Reduces pill burden	High, but competitive
Ezetimibe-bempedoic acid combination	Serves statin-intolerant patients	High
Long-acting delivery	Potential adherence benefit	Low near term because of development complexity

Ezetimibe has no approved injectable or biologic presentation. The most practical differentiated products remain oral.

What patents protect ezetimibe?

Ezetimibe’s original composition-of-matter and pharmaceutical-use patents were filed in the 1990s and have expired in the United States. The original product was developed by Schering-Plough, later acquired by Merck & Co.

Public patent records historically associated with Zetia and ezetimibe include U.S. Patent Nos. 5,846,966 and 6,207,822, among other related patents covering azetidinone compounds, pharmaceutical compositions, and cholesterol-treatment methods. Those rights are no longer a meaningful barrier to ordinary U.S. generic ezetimibe tablets. [2,3]

Current patent relevance

Patent category	Status for basic ezetimibe tablet
Original composition of matter	Expired
Original method of treatment	Expired or commercially weak
Standard immediate-release formulation	Generally open to generic competition
Fixed-dose combinations	Product- and claim-specific
Bempedoic acid/ezetimibe combinations	Potentially active patent estate
Novel solid dispersions	Potentially protectable
Pediatric or dysphagia formulations	Potentially protectable
Manufacturing processes	Potentially protectable if non-obvious and reproducible
Trade secrets	Relevant for process control, particle engineering, and scale-up

Patent analysis must distinguish between expired base-drug patents and active patents covering a particular combination or formulation. A company can commercialize generic ezetimibe while remaining exposed to claims directed to a specific co-formulation, process, or use.

When did ezetimibe lose exclusivity?

Zetia received U.S. approval in 2002. Its original regulatory exclusivity periods expired years ago, and generic ezetimibe entered the U.S. market in 2017 after patent litigation and settlement activity involving Merck and generic applicants.

The commercial exclusivity sequence was:

Event	Approximate timing
FDA approval of Zetia	2002
Original small-molecule exclusivity	Expired
Paragraph IV litigation involving ezetimibe	Primarily 2010s
First U.S. generic approvals	2017
Broad generic price competition	2017 onward
Current status	Mature generic market

The exact first-commercial-marketing rights of individual ANDA sponsors depended on their litigation outcomes and settlement terms. FDA’s Orange Book and approval records remain the controlling sources for product-specific listing and approval status. [4]

What is the Orange Book status of ezetimibe?

The Orange Book lists FDA-approved reference products and related patent and exclusivity information. Zetia’s original patent barriers are no longer the central issue for ordinary ezetimibe tablets. Generic applicants can rely on the reference product’s safety and efficacy findings through the ANDA pathway, subject to bioequivalence and labeling requirements.

Orange Book implications

For a standard ezetimibe tablet, the primary regulatory questions are:

1. Whether the proposed strength and dosage form correspond to the reference listed drug.
2. Whether the applicant must certify against any remaining listed patent.
3. Whether the product requires a Paragraph IV certification.
4. Whether formulation differences affect pharmaceutical equivalence or bioequivalence.
5. Whether the label includes the same indications, warnings, and administration instructions.

A novel dosage form, modified-release product, or combination product may not fit the ordinary ANDA pathway. Such products may require a 505(b)(2) application or a new drug application, depending on the formulation and clinical bridge.

Which companies challenged ezetimibe patents?

Generic companies challenged or contested Merck’s ezetimibe patent estate during the period preceding generic entry. Publicly reported participants included major ANDA sponsors such as Teva, Mylan, Sandoz, and Dr. Reddy’s Laboratories, although the precise litigation posture varied by patent, product, and settlement agreement.

The principal commercial outcome was delayed but eventual generic entry. The historical litigation no longer prevents ordinary generic ezetimibe sales, but it remains relevant for understanding launch timing, Paragraph IV strategy, and the value of formulation patents.

What patent litigation and settlements affect ezetimibe?

Historical ezetimibe litigation involved assertions of patents covering the active ingredient and related pharmaceutical products. Settlements reportedly permitted generic entry before the latest asserted patent expirations, subject to agreed dates and conditions.

For current diligence, the critical distinction is between:

• Expired litigation involving the original molecule.
• Active disputes involving fixed-dose combinations.
• Litigation over novel formulations or manufacturing methods.
• Patent challenges to bempedoic acid/ezetimibe products.
• Regulatory exclusivity attached to a specific combination or indication.

A new ezetimibe product should be screened against active U.S. patents for Nexlizet, combination products, and any formulation claims that read on the proposed dosage form. The risk is not captured by reviewing Zetia patents alone.

How does ezetimibe compare with competing lipid-lowering drugs?

Ezetimibe competes with statins, PCSK9 inhibitors, bempedoic acid, bile-acid sequestrants, fibrates, and omega-3 products. Its formulation profile is favorable because it uses a low daily dose and has no injection-device requirement.

Therapy	Main formulation advantage	Main commercial limitation
Ezetimibe	Low-dose oral tablet; generic supply	Low standalone price after generic entry
Atorvastatin and rosuvastatin	Highly established generic tablets	Muscle-related tolerability concerns
PCSK9 monoclonal antibodies	Strong LDL-C reduction	Injectable administration and high cost
Bempedoic acid	Oral option for statin-intolerant patients	Branded-product and patent exposure
Bempedoic acid/ezetimibe	Two mechanisms in one tablet	Combination patent and pricing risk
Bile-acid sequestrants	Non-systemic action	Large doses and gastrointestinal burden

The strongest commercial positioning for ezetimibe is as an adherence-enabling component of combination therapy, rather than as a premium standalone molecule.

What commercial opportunities exist for ezetimibe excipients?

1. Low-cost generic optimization

A manufacturer can improve gross margin through a robust excipient system that reduces:

• Blend segregation.
• Tablet weight variability.
• Compression defects.
• Dissolution failures.
• Over-lubrication sensitivity.
• Packaging requirements.

The opportunity is operational rather than price-based. Generic ezetimibe pricing is competitive, so yield, throughput, and release reliability have greater value than a marginally lower ingredient cost.

2. Excipient substitution

Potential substitutions include replacing lactose for patients or markets requiring lactose-free products, replacing sodium lauryl sulfate with another wetting system, or using directly compressible grades of microcrystalline cellulose and mannitol.

Substitution requires assessment of:

• Assay and content uniformity.
• Dissolution across pH conditions.
• Stability and impurity formation.
• Tablet hardness and friability.
• Bioequivalence.
• Labeling and inactive-ingredient controls.

An excipient change can create a 505(j) product if the final product remains pharmaceutically equivalent and bioequivalent. A more substantial formulation change may require a 505(b)(2) strategy.

3. Pediatric and geriatric products

Ezetimibe has potential for:

• Orally disintegrating tablets.
• Taste-masked chewable tablets.
• Low-volume oral suspensions.
• Sprinkle granules.
• Enteral-tube-compatible dispersions.

Taste masking is important because ezetimibe-containing products can have a bitter or unpleasant sensory profile. Ion-exchange resins, polymer coatings, lipid barriers, and flavor systems may be evaluated, although each increases formulation complexity.

4. Fixed-dose combinations

The combination market has the highest commercial value. Vytorin combines ezetimibe with simvastatin. Nexlizet combines ezetimibe with bempedoic acid. Further opportunities include combinations with atorvastatin, rosuvastatin, or other cardiovascular therapies where regulatory and patent conditions permit.

Combination products can support:

• Reduced pill burden.
• Improved adherence.
• Pharmacy substitution control.
• Premium pricing relative to commodity monotherapy.
• New method-of-use or formulation claims.

The key risk is patent infringement involving the partner drug, not ezetimibe itself.

5. Manufacturing and process patents

A commercially useful patent position could cover:

• Controlled particle-size ezetimibe.
• Continuous wet granulation.
• High-shear dispersion.
• Solvent-free amorphization.
• Moisture-controlled compression.
• Defined dissolution performance.
• Stabilized co-formulation with a statin or bempedoic acid.

Process patents are strongest when they deliver a measurable product attribute and have a narrow but enforceable relationship to the marketed product.

What generic entry risks exist for ezetimibe?

Ordinary ezetimibe tablets face low entry barriers. The principal risks are commercial:

• Multiple suppliers can compete on price.
• API and finished-dose capacity are available from several regions.
• Switching costs are limited.
• Reimbursement favors low-cost products.
• FDA approval does not guarantee durable pricing.
• Product differentiation is difficult without a new dosage form or combination.

Higher barriers may apply to:

• Ezetimibe-bempedoic acid combinations.
• Pediatric liquids.
• Taste-masked products.
• Stable amorphous dispersions.
• Products with demonstrated superiority in dissolution or adherence.
• Products requiring specialized containment or continuous processing.

Does ezetimibe have biosimilar risk?

No. Ezetimibe is a synthetic small molecule, not a biologic. It is subject to generic-drug competition through the ANDA framework rather than biosimilar competition under the Public Health Service Act.

The relevant regulatory risks are bioequivalence, pharmaceutical equivalence, formulation suitability, and patent certification. [4,5]

What is the FDA regulatory status of ezetimibe?

Ezetimibe is FDA-approved as a 10 mg oral tablet and in approved combination products. Generic ezetimibe products are approved through ANDAs. New delivery systems or combinations may require a 505(b)(2) application or a separate NDA.

The FDA’s inactive-ingredient database can support excipient selection, but prior use of an excipient does not eliminate the need to demonstrate product quality, safety, and performance. [6]

How strong is the ezetimibe patent estate?

The base ezetimibe estate is weak for new entrants because the original composition and basic tablet patents have expired. The estate is stronger for selected combination and formulation products.

Asset type	Patent strength	Commercial assessment
Generic 10 mg tablet	Low	Commodity market
Novel dissolution-enhanced tablet	Moderate	Depends on clinical and patent differentiation
ODT or chewable formulation	Moderate	Patient-segment opportunity
Pediatric liquid	Moderate	Regulatory and market-size constraints
Statin combination	Moderate to high	Depends on active partner-drug claims
Bempedoic acid combination	High relative to monotherapy	Patent and branded competition remain relevant
Manufacturing process	Moderate	Valuable if difficult to design around
Trade-secret process controls	Moderate	Important for cost and quality, not exclusivity

Key Takeaways

• Ezetimibe is a mature generic small molecule with expired core exclusivity.
• The reference tablet uses a conventional system built around lactose, microcrystalline cellulose, povidone, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.
• Low aqueous solubility creates opportunities in wetting, particle engineering, solid dispersion, and dissolution control.
• The best commercial opportunities are fixed-dose combinations, pediatric and geriatric delivery, orally disintegrating products, and manufacturing-cost improvements.
• Standard ezetimibe tablets face low patent and regulatory entry barriers.
• Combination products, particularly with bempedoic acid, require separate patent and freedom-to-operate analysis.
• Ezetimibe has no biosimilar risk because it is a synthetic small molecule.
• Patent value is shifting from the original molecule to formulations, combinations, manufacturing processes, and patient-specific delivery systems.

FAQs

Can ezetimibe be formulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, starch-based diluents, or other suitable excipients. The replacement must preserve dissolution, content uniformity, stability, and bioequivalence.

Is sodium lauryl sulfate necessary in an ezetimibe tablet?

No. It is a useful wetting agent but is not the only possible approach. A sponsor can evaluate alternative surfactants, particle-size reduction, hydrophilic polymers, or solid-dispersion technology.

Can an ezetimibe oral suspension obtain separate market exclusivity?

Potentially. A novel suspension may receive patent protection or regulatory exclusivity if it contains a non-obvious formulation, addresses a recognized patient population, and satisfies the applicable FDA pathway. Market size and stability will determine commercial value.

Is an ezetimibe-statin combination still commercially attractive?

Yes, but primarily where the product improves adherence, targets a defined dose combination, or offers a differentiated patient presentation. Generic statin competition makes cost control and regulatory positioning critical.

What is the most defensible ezetimibe formulation patent strategy?

The strongest strategy generally links a defined formulation or process to a measurable performance result, such as improved dissolution, reduced variability, enhanced stability, or successful bioequivalence at a difficult formulation target.

References

1. U.S. Food and Drug Administration. (2023). Zetia (ezetimibe) tablets prescribing information.
2. U.S. Patent No. 5,846,966. (1998). Azetidinone compounds useful as hypocholesterolemic agents.
3. U.S. Patent No. 6,207,822. (2001). Azetidinone compounds and pharmaceutical compositions.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly purified synthetic peptides.
6. U.S. Food and Drug Administration. (2024). Inactive ingredient database.